Drugs / UGX202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07311863 | Jan 2026 → Mar 2027 expected | retinitis pigmentosa | Suzhou UgeneX Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UGX202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07311863 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “the gene therapy drug UGX202” NCT07311863 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT07311863 ↗ |